CABALETTA BIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CABALETTA BIO, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $140.20M.
- CABALETTA BIO, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $5.75M.
- CABALETTA BIO, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $93.75M.
- CABALETTA BIO, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $24.88M.
- CABALETTA BIO, INC. stock issued during period, value, new issues for fiscal 2024 was $10.88M, a 94.14% decline from fiscal 2023.
- CABALETTA BIO, INC. stock issued during period, value, new issues for fiscal 2023 was $185.50M.
- CABALETTA BIO, INC. stock issued during period, value, new issues for fiscal 2021 was $48.25M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $140.20M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $10.88M 10-K · filed 2026-03-23 | |
| 2024-03-31 | $5.75M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $185.50M 10-K · filed 2025-03-31 | |
| 2023-06-30 | $93.75M 10-Q · filed 2024-11-14 | |
| 2021-12-31 | $48.25M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $24.88M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $7.67M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $2.17M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |